We acknowledge limitations to this study. Because sinusitis is diagnosed based on physical examination findings and symptoms, data not captured in NAMCS/NHAMCS, we were unable to determine which patients had acute bacterial sinusitis as strictly defined based on the criteria suggested by recent clinical guidelines. We were also not able to determine if patients receiving antibiotic treatment had recurrent sinusitis or had previously experienced treatment failure with narrow-spectrum therapy for sinusitis, either of which might have made prescription of a broad-spectrum agent acceptable. Previous studies have suggested, however, that bacterial sinusitis composes a relatively small fraction of acute sinusitis cases seen in primary care, and treatment failure is also uncommon. We were also unable to determine which patients had an allergy to recommended agents.

This study highlights that prescribing of broad-spectrum antibiotics for sinusitis, especially quinolones and macrolides, is extremely common. This is an important target for antimicrobial stewardship efforts partially because the benefits of antibiotic therapy are limited. Qualitative research to explore the health care provider and patient attitudes that influence antibiotic selection is a next step to understanding the problem. Also critically important are adoption of clinical guidelines that promote appropriate antibiotic use. Changes in prescribing behavior of health care providers for sinusitis are urgently needed to improve health care quality and stem the rising tide of antibiotic resistance in the United States.

Tarayn Fairlie, MD, MPH
Daniel J. Shapiro, BA
Adam L. Hersh, MD, PhD
Lauri A. Hicks, DO

Published Online: September 24, 2012. doi:10.1001/archinternmed.2012.4089

Author Affiliations: National Center for Immunization and Respiratory Diseases, Respiratory Diseases Branch, Centers for Disease Control & Prevention, Atlanta, Georgia (Drs Fairlie and Hicks); Division of General Pediatrics, Philip R. Lee Institute for Health Policy Studies, University of California, San Francisco (Mr Shapiro); and Division of Pediatric Infectious Diseases, University of Utah, Salt Lake City (Dr Hersh).

Correspondence: Dr Fairlie, National Center for Immunization and Respiratory Diseases, Centers for Disease Control & Prevention, 1600 Clifton Rd NE, MS C-25, Atlanta, GA 30333 (ly9@cdc.gov).

Author Contributions: Study concept and design: Fairlie, Shapiro, Hersh, and Hicks. Acquisition of data: Shapiro. Analysis and interpretation of data: Shapiro, Hersh, and Hicks. Drafting of the manuscript: Fairlie and Hicks. Critical revision of the manuscript for important intellectual content: Fairlie, Shapiro, Hersh, and Hicks. Statistical analysis: Fairlie, Shapiro, Hersh, and Hicks. Obtained funding: Hersh. Study supervision: Hicks.

Financial Disclosure: None reported.

Disclaimer: The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control & Prevention.


Periprocedural Management of the Patient With Diabetes Mellitus Undergoing Coronary Angiography: Current Practice

Despite advances in procedural technique and pharmacotherapy, patients with diabetes mellitus (DM) experience worse outcomes than patients without DM undergoing percutaneous coronary intervention (PCI). Periprocedural hyperglycemia is associated with adverse clinical outcomes in patients undergoing PCI, and studies have suggested that treating periprocedural hyperglycemia may improve outcomes by attenuating glucose-mediated ischemic injury at the time of PCI. Simple preventive strategies, such as continuing long-acting hypoglycemic medications, have not been evaluated, and there are no guidelines for periprocedural use of these medications.

We conducted an anonymous electronic survey of cardiologists referring patients for coronary angiography using the American Heart Association Cardiology Fellows Society of Greater New York and the Society of Cardiovascular Angiography and Interventions from March through July 2011. Of the 144 survey responders, 24% were fellows-in-training, and 33% were faculty at a medical school. Among this cohort, 60% believed that hyperglycemia at the time of PCI is harmful, and 94% believed that hypoglycemia at the time of PCI is harmful. Although most clinicians routinely hold oral hypoglycemic medications prior to angiography, substantial numbers do not, with nearly half routinely continuing thiazolidinediones on the morning of coronary angiography (Table). Clinicians are more likely to continue insulin-based regimens than oral medications, but again there is no uniformity of practice. In patients with uncontrolled DM (glycosylated hemoglobin level >10% or blood glucose levels >200 mg/dL), a little more than one-third of physicians reported they would change their usual practice and continue hypoglycemic medications prior to coronary angiography. (To convert glycosylated hemoglobin to a proportion of total hemoglobin, multiply by 0.01; to convert serum glucose to millimoles per liter, multiply by 0.0555.)

**Table. Clinicians Reporting Routine Holding of Hypoglycemic Medications Prior to Coronary Angiography**

<table>
<thead>
<tr>
<th></th>
<th>Sulfonylurea</th>
<th>Metformin</th>
<th>Thiazolidinedione</th>
<th>NPH Insulin</th>
<th>Glargine-Insulin</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hold Dose</td>
<td>70 (39)</td>
<td>88 (12)</td>
<td>55 (34)</td>
<td>26 (35)</td>
<td>63 (55)</td>
</tr>
<tr>
<td>Continue</td>
<td>100 (62)</td>
<td>100 (2)</td>
<td>100 (67)</td>
<td>100 (78)</td>
<td>100 (88)</td>
</tr>
<tr>
<td>Half-Dose</td>
<td>72 (44)</td>
<td>72 (2)</td>
<td>72 (46)</td>
<td>72 (58)</td>
<td>72 (88)</td>
</tr>
</tbody>
</table>

Abbreviations: DM, diabetes mellitus; NPH, neutral protamine Hagedorn.

a Data are presented as percentage of survey responders who report routinely holding hypoglycemic medications prior to procedure in patients with DM referred for coronary angiography (percentage of those who routinely hold but will continue medication in uncontrolled DM, defined as glycosylated hemoglobin level >10% or blood glucose levels > 200 mg/dL [to convert glycosylated hemoglobin to a proportion of total hemoglobin, multiply by 0.01; to convert serum glucose to millimoles per liter, multiply by 0.0555]).

b 70/30 insulin consists of 70% long-acting NPH and 30% short-acting or rapid-acting insulin.

c Twenty-eight percent of survey responders hold metformin for 48 hours before and 48 hours after procedure.

d Survey responders who report continuing half-dose insulin prior to procedure were not asked if they would change their strategy in patients with uncontrolled DM.

The risk of hypoglycemia seems to be a major factor preventing physicians from continuing long-acting hypoglycemic medications prior to PCI. Delays in scheduled cardiac catheterization procedures frequently occur, and, therefore, uncertainty exists regarding how long a patient will be fasting prior to his or her coronary angiogram. However, hypoglycemia is not likely to complicate routine coronary angiography because patients with a procedure scheduled for late afternoon are usually given permission to have a light breakfast and to eat relatively soon after the procedure is completed even when conscious sedation is administered. Furthermore, there is substantial variability in eating patterns and stress levels on the day of PCI, which may lead to hyperglycemia at the time of arterial access. This may explain why most physicians report continuing at least half the dose of long-acting insulin in all patients with DM prior to angiography.

Our data suggest that physicians are influenced by the pharmacologic properties of the various hypoglycemic agents when designing management strategies for patients with DM undergoing coronary angiography. For example, thiazolidinediones and glargine-insulin are unlikely to cause sudden hypoglycemia in the setting of variable eating patterns. Physicians are, therefore, less likely to hold thiazolidinediones compared with sulfonylureas prior to cardiac catheterization. Similarly, physicians are more likely to continue full-dose glargine-insulin than neutral protamine Hagedorn (NPH)-insulin on the day of coronary angiography. Thus, it is a cause for concern that the management of patients treated with metformin reflects a lack of knowledge of the pharmacologic properties of this drug. Metformin is contra-indicated in patients with chronic kidney disease owing to the risk of lactic acidosis at very high metformin concentrations. However, in patients with normal kidney function, renal failure is unlikely to change following angiography unless contrast-induced nephropathy develops, a complication that occurs 48 to 72 hours after contrast exposure. The half-life of metformin is 2 to 5 hours, and, therefore, the drug label instructs patients to stop the medication for 48 hours after contrast exposure. Nevertheless, 88% of physicians in the current survey report holding metformin prior to coronary angiography. Furthermore, of these physicians, 28% report holding metformin for both 2 days before and 2 days after coronary angiography.

Although the response rate to this survey was low, and we have no data on nonresponders, we obtained a sample of physicians at various stages of practice, including fellows-in-training and attending physicians, in both private practice and academics. Survey responders may also have self-selecting features. For example, only those who believe this is an important topic of discussion may have responded to the survey. However, we still demonstrate clinical equipoise in the management of hypoglycemic medications in the patient with DM undergoing coronary angiography.

We conclude that there is considerable variability in the management of hypoglycemic medications by cardiologists sending patients for coronary angiography. An evidence base to better establish optimal goals for glycemic control in the setting of PCI and education of physicians to avoid premature discontinuation of DM therapies is needed. Furthermore, prospective randomized studies are warranted to determine if continuing long-acting hypoglycemic medications prior to PCI is safe and has a beneficial effect on long-term clinical outcomes.

Binita Shah, MD, MS
Ann Danoff, MD
Martha J. Radford, MD
Linda Rolnitzky, MS
Steven P. Sedlis, MD


Author Affiliations: Department of Medicine, Divisions of Cardiology (Drs Shah and Sedlis) and Endocrinology (Dr Danoff), VA New York Harbor Health Care System, New York Campus, New York; and Department of Medicine, Division of Cardiology (Drs Shah and Radford), and Department of Environmental Medicine, Division of Biostatistics (Ms Rolnitzky), New York University School of Medicine, New York.

Correspondence: Dr Sedlis, Department of Medicine, Division of Cardiology, VA New York Harbor Health Care System New York Campus, 423 E 23rd St, 12 West, New York, NY 10010 (steven.sedlis@nyumc.org).

Author Contributions: Dr Sedlis had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Shah, Danoff, and Sedlis. Acquisition of data: Shah. Analysis and interpretation of data: Shah.
Shah, Danoff, Radford, Rolnitzky, and Sedlis. **Drafting of the manuscript:** Shah and Sedlis. **Critical revision of the manuscript for important intellectual content:** Shah, Danoff, Radford, and Rolnitzky. **Statistical analysis:** Shah and Rolnitzky. **Administrative, technical, and material support:** Shah. **Study supervision:** Danoff and Sedlis.

**Financial Disclosure:** None reported.

**Funding/Support:** This study was supported in part by grant 1UL1RR029893 from the National Center for Research Resources, National Institutes of Health.

**Additional Contributions:** We greatly appreciate all the cardiologists who participated in this survey. We thank Georgina Lopez-Cruz and Khusrow Niazi, MD, from SCAI, Susan Bishop and Mary Gonzalez from the AHA Cardiology Fellows Society of Greater New York, and Rebecca Ortega and Sohah Iqbal, MD, from the Society for Cardiovascular Angiography and Interventions—Women in Innovations organization for distributing this electronic survey to their respective organizations.


**Caregivers’ Perceptions of Patients as Reminders to Improve Hand Hygiene**

Hand hygiene is widely regarded as the most important measure to prevent healthcare-associated infections and limit the spread of antimicrobial resistance. However, healthcare worker (HCW) compliance remains low. Successful strategies to improve compliance result from a combination of multiple components, including system change, training, and education of HCWs; observation and performance feedback; reminders in the workplace; and the institution of a safety climate. A promising, albeit less explored, approach is to encourage patients to remind HCWs to perform hand hygiene before caring for them. This strategy has been recommended by a large number of organizations and authorities worldwide, including the World Health Organization and the US Centers for Disease Control and Prevention. However, very little is known about HCWs’ views of such programs. We surveyed a sample of HCWs to investigate the degree to which they wish to be reminded by patients to perform hand hygiene and to identify sociodemographic variables and beliefs influencing their views.

**Methods.** We conducted a cross-sectional study in 2009 to assess HCWs’ perceptions of a hypothetical patient participation program to improve staff compliance with hand hygiene at the University of Geneva Hospitals (HUG), Geneva, Switzerland. An anonymous, confidential survey was sent to the home address of 700 randomly selected HCWs. Attitudes and beliefs were assessed using a Likert scale ranging from 1 (strongly agree) to 5 (strongly disagree). We also assessed the level of acceptance of wearing a badge to invite patients to ask about hand hygiene, previously suggested as a powerful patient incentive. Variables associated with support of patient inquiry were assessed through univariate and multivariate logistic regression. Answers were dichotomized to simplify reporting. We performed a forward stepwise logistic regression procedure introducing one by one all covariates using P < .05 for entry. We presented a parsimonious model including all covariates significantly associated with support of patient inquiry to improve hand hygiene. All tests were 2-sided, and P < .05 indicated statistical significance.

**Results.** Of the 277 respondents (response rate, 41.4%), 44% were physicians, and 56% were nurses; 65% had more than 10 years’ work experience. Thirty percent had been asked by a patient whether they had cleansed their hands before being cared for in the previous month. Although 74% believed that patients could help prevent healthcare-associated infections, 29% of respondents did not support the idea of being reminded by patients to perform hand hygiene, 27% believed that such an inquiry is not part of the patients’ role, and 37% would not consent to wear a badge inviting patients to ask about hand hygiene. Seventy respondents (26%) considered that inviting patients to inquire about staff hand hygiene would be too time consuming, 17% believed that patient inquiry would be upsetting, and 27% felt that it would be humiliating. Forty-four percent admitted to a feeling of guilt if patients discovered that they omitted hand hygiene, and 43% would be ashamed to disclose that they forgot to cleanse their hands. Forty-six percent feared that acknowledging omission could stir patient anger, and 26% believed that it would make them seem inept. Interestingly, 18% feared that admitting their omission to perform hand hygiene could lead to legal action.

By multivariate analysis (Table), endorsement of patient inquiry was independently associated with the beliefs that patients can help prevent medical errors and that patient inquiry can improve HCWs’ hand hygiene behavior. By contrast, endorsement was inversely associated with the belief that omitting hand hygiene is inconsequential, the perception that patient inquiry would be humiliating to HCWs, and that such a strategy would call into question their competency.